---
title: "GSK Updates Market on Total Voting Rights and Share Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294705563.md"
description: "GlaxoSmithKline announced that as of July 31, 2026, its issued share capital comprises over 4.3 billion ordinary shares, with approximately 271 million held in treasury, resulting in 4.045 billion voting rights. This disclosure, required by UK FCA rules, clarifies the denominator for shareholders calculating notification obligations. The announcement aims to support transparency and regulatory compliance within GSK's shareholder base."
datetime: "2026-08-03T14:03:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294705563.md)
  - [en](https://longbridge.com/en/news/294705563.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294705563.md)
generator: "portal-rs"
---

# GSK Updates Market on Total Voting Rights and Share Capital

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK has reported that as of 31 July 2026 its issued share capital comprised more than 4.3 billion ordinary shares, of which around 271 million are held in treasury, resulting in a total of 4.045 billion voting rights. The disclosure, made under UK Financial Conduct Authority rules, clarifies the denominator shareholders must use when calculating whether they are obliged to notify changes in their holdings, supporting transparency and regulatory compliance in the company’s shareholder base.

The most recent analyst rating on (GB:GSK) stock is a Buy  
 with a £30.10 price target.  
 To see the full list of analyst forecasts on GlaxoSmithKline stock,  
 see the GB:GSK Stock Forecast page. 

**Spark’s Take on GSK Stock**

According to Spark, TipRanks’ AI Analyst, GSK is a Outperform.

The score is driven primarily by strong profitability and solid free-cash-flow generation, supported by reasonable valuation and an attractive dividend yield. The main constraints are balance-sheet leverage and uneven earnings/cash conversion, while technicals are moderately positive based on price being above major moving averages (with limited momentum data available).

To see Spark’s full report on GSK stock,  
 click here. 

**More about GlaxoSmithKline**

GSK is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines that help prevent and treat disease worldwide. The group operates across major therapeutic areas with a broad portfolio, positioning it as a leading player in the global healthcare and life sciences industry.

**Average Trading Volume:** 8,255,854

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** £77.4B

See more data about GSK stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [Deutsche Bank  Sticks to Its Hold Rating for GlaxoSmithKline (GSK)](https://longbridge.com/en/news/297776249.md)
- [GSK to advance mRNA flu vaccine to late-stage trial](https://longbridge.com/en/news/297605972.md)
- [GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors](https://longbridge.com/en/news/297654888.md)
- [Jemperli accepted for priority review by US FDA](https://longbridge.com/en/news/298022487.md)
- [HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy](https://longbridge.com/en/news/297942710.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**